Phosphagen. Share Discussion Threads

[lgw] 13/11/2006 11:25

rambutan2 can you paste the link to the presentation for me can only find may one.
tia

[rambutan2] 13/11/2006 10:35

no, two separate pieces. the investor presentation will have been related to the recent agm, the newsletter is a regular quarterly thing.

[lgw] 13/11/2006 10:11

I cant seem to access the investor presentation released today, but was very impressed with the november newsletter on the psg website, is this the article referred to in todays rns?.

[lbo] 13/11/2006 08:33

The UK's healthcare sector remains prone to merger and acquisitions, according to provisional figures from the Office of National Statistics (ONS). Apart from big pharma acquiring biotech, recent M&As may change market dynamics and the suppliers of raw materials for pharmaceutical production.

In their quarterly analysis of M&A activity, the ONS estimate that expenditure on UK acquisitions by UK companies increased from £4.2 billion in Q2 to £11.1 billion in Q3 2006. This compares to £6.8 billion in Q1. Boot's acquisition of Alliance Unichem to form Alliance Boots accounted for a reported £3.4 billion. Alliance Boots are involved in Pfizer's controversial move to a single distribution channel for POMs in the UK.

Expenditure on acquisitions abroad by UK companies increased from £3.3 billion in Q2 to £6.7 billion in Q3 2006. This compares to £7.4 billion in Q1. For example, during Q3:

- ICI disposed of Uniqema, a Dutch speciality chemical company, which was purchased by Croda International for £410 million. Croda provide ingredients for the nutritional, pharmaceutical and animal health care markets among many other sectors.

- Sage Group, which supplies business management software and services, bought US-based Emdeon Practice Services Inc for £297 million. Emdeon Practice Services produce electronic health records and other software allowing practices to automate clinical and practice management workflow.

Expenditure on UK acquisitions by foreign companies decreased slightly from £18.4 billion in Q2 to £18.1 billion in Q3 2006. This compares to £24.1 billion in Q1. Again, healthcare-related acquisition accounted for a significant proportion. Linde AG bought the BOC group in a deal worth a reported £8.2 billion. The new company will trade under the name "The Linde Group". Linde is a leading supplier of industrial and medical gases and says it plans to expand its "fast-growing" healthcare section.

Meanwhile, Novartis acquired NeuTec Pharma for a reported £305 million.
NeuTec, a biopharmaceutical company formed in 1997, develops genetically recombinant antibodies against infections such as systemic candidiasis and Staphylococcus aureus including MRSA. The antibodies increase the pathogen's susceptibility against antibiotics.

This is another example of the continuing trend for big pharma to acquire biotech companies. During Q2, AstraZeneca acquired Cambridge Antibody Technology for a reported £702 million.

Overall, the provisional figure suggest that UK companies made 86 acquisitions abroad, while foreign companies made 58 UK acquisitions. There were 148 domestic acquisitions during Q3. This compares to 92, 59 and 205 respectively during Q2.

[donaferentes] 09/11/2006 17:42

Suesean, a propos your post, I posted this elsewhere in Feb 2005, which underlines Nestle's view of the future for Nutraceuticals.

Peter Brabeck, head of Nestle and one of the most influential
people in the food industry, was interviewed in yesterdays Financial
Times:-

"It is my conviction that the next value creation, and it will be huge,
is going to be nutritional aspects. That is what allows you to ask 40%
more for your products".

The article continued that foods with medical benefits, otherwise known
as functional foods or nutraceuticals are expected to be the big source of
growth for the next 15 to 20 years.

- for full article - see last 3 paragraphs.

[spaceparallax] 09/11/2006 12:58

Sue,

Thanks for that.

[suesean1] 09/11/2006 12:53

Get the latest Market Reports on
Novartis
Nestle

Related News

Coca-Cola, Nestlé scale down drinks venture
Nestlé backtracks after re-branding blunder
Nestlé enjoys strong organic growth
Nestle France outsources transport logistics
Nestle shifts Smarties production
Nestlé to build fresh factory for Nespresso
Sweet profits for Nestle despite rising costs





News Archives

All news for November 2006
All news for October 2006


09/11/2006 - Nestlé is tipped as a potential buyer of Novartis' nutritional supplements unit, rumoured to be up for sale, as the Swiss food group is aiming to strengthen its position in the health and nutrition sector.

The unit, which makes nutritional supplements – both oral and tube delivery – for use in hospitals and nursing homes, forms part of the Novatis' consumer division. There has also been speculation since last month that Nestlé will snap up another of Novatis' consumer units, Gerber baby-foods.
Nestlé has stated that health, wellness and nutrition are presently an acquisition priority. Recent moves in this area include the acquisition of weight loss consultation company Jenny Craig for US$600m in July, and Uncle Toby's cereals and nutritional snacks business in Australia.

It has also obtained the option to licence Phospha E for use in nutritional products aimed at metabolic syndrome from Australian biotech company Phosphagenics, in exchange for a contribution towards the costs of a preclinical study, prior to full-scale evaluation in humans.

Through a joint venture with Coca-Cola, it recently launched a green tea-based functional drink called Enviga in the United States, with European roll-out scheduled for 2007.

Nestlé Nutrition is an autonomous unit within the group, and it already has a global presence in infant nutrition, health care nutrition and performance nutrition. For the first nine months of the current fiscal year the nutrition unit reported sales of CHF4.3m (€2.7m), up from CHF 3.8m (€2.4m) for the prior year period.

Press reports claim that two sources close to Novartis say that the pharmaceutical giant is being advised on the nutritional supplement sale – which could be worth more than US$1bn (€0.78bn at current exchange rates)– by Goldman Sachs. No official statement has been made by Novartis, Goldman Sachs or Nestlé.

Novartis acquired the division from Bristol Myers Squibb in 2004 for $385m (€301m).

According to analysts, Novartis' consumer division is regarded as a "less core" part of the overall business, and may be tapped as a source of funds when needed. In March it sold its Nutrition and Sante health food unit to ABN Amro Holding for €220m – the last step in the divestment of its food concerns that began in 2002

[ladybird1] 07/11/2006 18:10

Nothing. Typical behaviour of this sort of small(ish), 'hope' stock - people not aleady in inactive until the next piece of news and there are always a few sellers for various reasons. The stock drifts down until it reaches a probably undervalued level where bargain hunters are tempted. 12-13p seems a reasonable support level, probably dipping a bit further first, assuming no news likely before next year.

[spaceparallax] 07/11/2006 16:14

What do you think is wrong?

[hopeless698] 07/11/2006 15:16

i don't agree...theres something wrong

[spaceparallax] 07/11/2006 13:46

LBO,

I'm with you on that.

[lbo] 07/11/2006 13:17

A lot of M&A in the sector and I suspect the mms are taking the opportunity to flush out weak holders. 12-13p support and a quick rise to new highs over 17p IMHO.

[lgw] 06/11/2006 16:33

rubbish its just drifting on lack of news.

[hopeless698] 06/11/2006 16:31

it's gone down quite alot recently for no apparent reason...looks a bit scary

[hopeless698] 06/11/2006 16:31

it's gone down quite alot recently for no apparent reason...looks a bit scary

[spaceparallax] 06/11/2006 15:23

I feel a top-up approaching.

[blackbear] 05/11/2006 00:13

What kind of animals do they experiment on chimpanzees?

[donaferentes] 04/11/2006 21:44

Nothing to do but wait patiently. I too am here because, as Serratia says it has "potential general applicability of the technology." Impossible to say what its worth is, except a long way north of here, when its first major drug platform gets FDA approval - some time away yet I imagine.

I've had a small stake in as a book mark for over a year now, to which I may add nearer the time when true take off happens and solid revenues start to flow.

[lgw] 03/11/2006 20:42

dissapointing all this drifting,I'm still holding for the rerating long overdue.

[lbo] 03/11/2006 09:02

The Times November 03, 2006

AstraZeneca urged to put £4bn cash pile to use
By Robin Pagnamenta

Major shareholders in AstraZeneca are demanding that executives at the pharmaceuticals group plunder its $4 billion (£2.1 billion) cash pile to rebuild its weak pipeline of new drugs with new acquisitions, The Times has learnt. David Brennan, the new chief executive, and other board members are to meet some of the company's biggest shareholders this month to explain the group's third-quarter figures.

"The obvious question to ask is, 'What are you going to do about the pipeline?' " said Gareth Powell, fund manager at AXA Framlington, which owns 15 million shares or 1 per cent of AstraZeneca. "They are going to have to go out, be aggressive and buy smaller companies."

John Wilson, investment director at Standard Life, which owns 17 million shares in the company, said: "It generates wads of cash but the question is what it does with it. It needs to find deals that are going to make it work."

Shareholders have grown increasingly alarmed in recent months by the withdrawal from development of four key drugs once viewed as central to the company's future revenues - Cerovive, an anti-stroke drug, Galida, a diabetes treatment, Exanta, a blood-clot drug, and Iressa, for lung-cancer sufferers.

The company's current product range is performing well, but there is a yawning gap opening up as patents start to expire. Mr Brennan now faces calls to buy in new technology.

Anne-Marieke Ezendam, fund manager at Threadneedle Investments, which owns 13 million shares, said: "I think we will have a discussion about whether AstraZeneca should go out and buy products or companies."

[hopeless698] 03/11/2006 08:41

looks a bit dodgy! down again today

[spaceparallax] 02/11/2006 13:04

Surprised at the share price fall - I was under the impression that recent trading has been majority Buys.

[spaceparallax] 12/10/2006 09:45

The good news continues - it would be nice if PSG could map out the next steps.

[suesean1] 12/10/2006 08:12

For immediate release
12 October 2006

Completion of Phosphagenics' transdermal insulin (TPM-02/Insulin) clinical
trial confirms the successful delivery of insulin across skin in humans

Melbourne, Australia, 12 October 2006: Phosphagenics Limited ("Phosphagenics")
(ASX: POH; AIM: PSG) announced today that it has received the final report of
its Phase I transdermal insulin clinical trial.

The final report confirms the conclusions of the interim results announced in
August, that Phosphagenics had successfully delivered insulin through the skin
in humans by means of its patented TPM-02/Insulin delivery system. The key
findings, as previously announced, were that TPM-02/Insulin, when applied as a
gel, delivered insulin through the skin and into the bloodstream and exerted a
physiological effect of lowering blood glucose levels. Importantly, TPM-02/
Insulin did not produce any adverse reactions.

A new finding, contained in the final study report, was the detection of
exogenous insulin (externally-applied insulin) in the circulation of volunteers
who received TPM-02/Insulin. This additional data, in conjunction with the
blood glucose, endogenous insulin and c-peptide results of the trial announced
in August, demonstrate the ability of TPM-02/Insulin to deliver insulin into
the blood stream to produce significant physiological effects